参考文献/References:
［1］Patankar S, Burke WM, Hou JY, et al Risk stratification and outcomes of women undergoing surgery for ovarian cancer ［J］. Gynecol Oncol, 2015, 138 (1): 62-69.
［2］Grimm C, Harter P, Alesina PF, et al. The impact of type and number of bowel resections on anastomotic leakage risk in advanced ovarian cancer surgery ［J］. Gynecol Oncol, 2017, 146 (3): 498-503.
［3］Mahdi H, Gojayev A, Buechel M, et al. Surgical site infection in women undergoing surgery for gynecologic cancer ［J］. International Journal of Gynecological Cancer, 2014, 24 (4): 779-786.
［4］Jaeger W, Ackermann S, Kessler H, et al. The effect of bowel resection on survival in advanced epithelial ovarian cancer ［J］. Gynecol Oncol, 2001, 83 (2): 286-291.
［5］Heng S,Hardy J,Good P.A retrospective audit on usage of Diatrizoate Meglumine (Gastrografin) for intestinal obstruction or constipation in patients with advanced neoplasms ［J］. Palliative Medicine, 2017，32（1）:269216317726430.
［6］Khatib G,Guzel AB,Gulec UK.A novel technique: Carbon dioxide gas-assisted total peritonectomy, diaphragm and intestinal meso stripping in open surgery for advanced ovarian cancer (Cukurova technique) ［J］. Gynecol Oncol, 2017, 146 (3): 674-675.
［7］Prat J. Staging classification for cancer of the ovary,fallopian tube,and peritoneum:abridged republication of guidelines from the international federation of gynecology and obstetrics(FIGO) ［J］. Obstetrics & Gynecology, 2015, 126 (1): 171.
［8］Powless CA, Aletti GD, Bakkum-Gamez JN, et al. Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: Implications for surgical staging ［J］. Gynecol Oncol, 2011, 122 (3): 536-540.
［9］Morice P, Pautier P, Lhomme C, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes in optimally debulked advanced ovarian cancer: A randomized clinical trial ［J］. J Natl Cancer Inst, 2005, 97 (21): 1620-1621.
［10］Chang SJ, Bristow RE, Chi DS, et al.Role of aggressive surgical cytoreduction in advanced ovarian cancer ［J］. J Gynecol Oncol, 2015, 26 (4): 336-342.
［11］Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer ［J］. N Engl J Med, 2011, 365 (26): 2484-2496.
［12］Tran CW, Mcgree ME, Weaver AL, et al. Surgical site infection after primary surgery for epithelial ovarian cancer: Predictors and impact on survival［J］. Gynecol Oncol, 2015, 136(2): 278-284.
［13］Edmiston CJ, Bruden B, Rucinski MC, et al. Reducing the risk of surgical site infections:Does chlorhexidine gluconate provide a risk reduction benefit? ［J］. Am J Infect Control, 2013, 41(5 Suppl): S49-S55.
［14］Van Der Slegt J, Van Der Laan L, Veen EJ, et al. Implementation of a bundle of care to reduce surgical site infections in patients undergoing vascular surgery ［J］. PLoS One, 2013, 8 (8): e71566.
［15］Saeed MJ, Dubberke ER, Fraser VJ. Procedure-specific surgical site infection incidence varies widely within certain National Healthcare Safety Network surgery groups ［J］. Am J Infect Control, 2015, 43 (6): 617-623.
［16］Fader AN, Weise RM, Sinno AK, et al. Utilization of minimally invasive surgery in endometrial cancer care:a quality and cost disparity ［J］. Obstetrics & Gynecology, 2016, 127 (1): 91.
［17］周学惠晚期上皮性卵巢癌肠肿瘤切除的作用 ［J］临床肿瘤学杂志，2005，10（4）：366-369
［18］Abdul S, Tidy JA, Paterson ML. Can we identify the patients who are likely to undergo bowel resectionat the time of surgery for ovarian cancer? ［J］. Journal of Obstetrics & Gynaecology the Journal of the Institute of Obstetrics & Gynaecology, 2006, 26 (4): 357.
［19］CAI H-b, ZHOU Y-f, CHEN H-z, et al. The role of bowel surgery with cytoreduction for epithelial ovarian cancer ［J］. Clin Oncol, 2007, 19 (10): 757.
［20］纪新强，尹吉梅卵巢癌肠转移的手术治疗 ［J］现代妇产科进展，2000，9（5）：361-362
［21］覃金春，李力，陈昌贤，等卵巢癌手术中肠道病灶处理对预后影响的循证评价 ［J］广西医科大学学报，2012，29（4）：547-552
［22］Morris MS, Graham LA, Chu DI, et al. Oral antibiotic bowel preparation significantly reduces surgical site infection rates and readmission rates in elective colorectal surgery ［J］. Journal of the American College of Surgeons，2014,219（3）：S 18-S 19.
［23］Lim MC, Kang S, Song YJ, et al. Feasibility and safety of extensive upper abdominal surgery in elderly patients with advanced epithelial ovarian cancer ［J］. J Korean Med Sci, 2010, 25 (7): 1034-1040.
［24］Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial ［J］. Lancet Oncol, 2013, 14 (10): 1020-1026.
［25］Dolejs SC, Guzman MJ, Fajardo AD, et al. Bowel preparation is associated with reduced morbidity in elderly patients undergoing elective colectomy ［J］. Journal of Gastrointestinal Surgery, 2017, 21 (2): 372-379.
［26］Deierhoi RJ, Dawes LG, Vick CA, et al. Choice of intravenous antibiotic prophylaxis for colorectal surgery does matter ［J］. J Am Coll Surg, 2013, 217 (5): 763-769.
［27］Plotti F, Montera R, Aloisi A, et al. Total rectosigmoidectomy versus partial rectal resection in primary debulking surgery for advanced ovarian cancer ［J］. EJSO, 2016, 42 (3): 383-390.
［28］Ledermann JA, Harter P, Gourley CA, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm) ［J］. Journal of Clinical Oncology, 2013, 31 (15, S): 1382-1392.
［29］Gotlieb WH, Amant F, Advani S, et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study ［J］. Lancet Oncology, 2012, 13 (2): 154-162.
［30］Monk BJ, Huang HQ, Burger RA, et al. Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: A Gynecologic Oncology Group Study ［J］. Gynecol Oncol, 2013, 128(3): 573-578.